Herceptin Biosimilar Market: Will "Interchangeability" Drive the Next Wave of Growth? The oncology market in 2026 is witnessing a massive transition as trastuzumab biosimilars reach a global valuation of approximately $4.09 billion. While the original blockbuster biologic, Herceptin, defined the standard of care for HER2-positive cancers for decades, 2026 marks a year where biosimilars have officially captured over 50% of the total trastuzumab revenue share. The most significant...
จองคิวบริการ
NR tours
Youplay
NR shop
NR jobs
facebook th
thai
English
French
Spanish
Portuguese
Italiano
Romaian
china